<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736449</url>
  </required_header>
  <id_info>
    <org_study_id>IRB1108</org_study_id>
    <nct_id>NCT01736449</nct_id>
  </id_info>
  <brief_title>Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management</brief_title>
  <official_title>Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the
      surface of the cornea. Frequently, these pterygia will recur even after surgical resection.
      Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of
      bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study
      is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab
      versus pterygium excision alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective trial. Thirty-one patients with a primary pterygium of at least 2 mm in
      size and without any previous ocular surgery will be included. Outcome measures will include
      best corrected visual acuity, intraocular pressure, recurrence, and any sight threatening
      complications at two weeks, two months, and six months postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of recurrent pterygia with postoperative bevacizumab</measure>
    <time_frame>6 months</time_frame>
    <description>The number of recurrent pterygia with patients who received bevacizumab after pterygium excision was compared to the number of recurrences in those patients who only had pterygium excision.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>Pterygium Excision Alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pterygium Excision with Bevacizumab Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Pterygium Excision with Bevacizumab Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any patient 18 years of age or older with a primary pterygium that extends at least 2
             mm past the limbus

        Exclusion Criteria:

          -  history of glaucoma

          -  previous ocular surgery

          -  steroid-response glaucoma

          -  previous myocardial infarct

          -  bleeding disorder

          -  pregnancy

          -  lack of patient cooperation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Keith Tokuhara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arrowhead Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arrowhead Regional Medical Center</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Detorakis ET, Spandidos DA. Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (Review). Int J Mol Med. 2009 Apr;23(4):439-47. Review.</citation>
    <PMID>19288018</PMID>
  </reference>
  <reference>
    <citation>Detorakis ET, Zaravinos A, Spandidos DA. Growth factor expression in ophthalmic pterygia and normal conjunctiva. Int J Mol Med. 2010 Apr;25(4):513-6.</citation>
    <PMID>20198298</PMID>
  </reference>
  <reference>
    <citation>Avisar R, Arnon A, Avisar E, Weinberger D. Primary pterygium recurrence time. Isr Med Assoc J. 2001 Nov;3(11):836-7.</citation>
    <PMID>11729580</PMID>
  </reference>
  <reference>
    <citation>Hirst LW. The treatment of pterygium. Surv Ophthalmol. 2003 Mar-Apr;48(2):145-80. Review.</citation>
    <PMID>12686302</PMID>
  </reference>
  <reference>
    <citation>Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007 Jul;18(4):308-13. Review.</citation>
    <PMID>17568207</PMID>
  </reference>
  <reference>
    <citation>Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K, Suwan-Apichon O. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea. 2011 Nov;30(11):1213-8. doi: 10.1097/ICO.0b013e31821c9b44.</citation>
    <PMID>21915047</PMID>
  </reference>
  <reference>
    <citation>Fallah Tafti MR, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea. 2011 Feb;30(2):127-9. doi: 10.1097/ICO.0b013e3181e16d67.</citation>
    <PMID>20885313</PMID>
  </reference>
  <reference>
    <citation>Banifatemi M, Razeghinejad MR, Hosseini H, Gholampour A. Bevacizumab and ocular wound healing after primary pterygium excision. J Ocul Pharmacol Ther. 2011 Feb;27(1):17-21. doi: 10.1089/jop.2010.0094. Epub 2010 Oct 26.</citation>
    <PMID>20977367</PMID>
  </reference>
  <reference>
    <citation>Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010;43(3):134-8. doi: 10.1159/000252980. Epub 2009 Oct 29.</citation>
    <PMID>19887878</PMID>
  </reference>
  <reference>
    <citation>Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea. 2012 Feb;31(2):155-61. doi: 10.1097/ICO.0b013e3182151e0e.</citation>
    <PMID>22081150</PMID>
  </reference>
  <reference>
    <citation>Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res. 2010 Jan;35(1):17-22. doi: 10.3109/02713680903395273.</citation>
    <PMID>20021250</PMID>
  </reference>
  <reference>
    <citation>Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi RF. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea. 2011 Nov;30(11):1219-22. doi: 10.1097/ICO.0b013e31820ca63f.</citation>
    <PMID>21955635</PMID>
  </reference>
  <reference>
    <citation>Cortez RT, Ramirez G, Collet L, Thakuria P, Giuliari GP. Intravitreous bevacizumab injection: an experimental study in New Zealand white rabbits. Arch Ophthalmol. 2010 Jul;128(7):884-7. doi: 10.1001/archophthalmol.2010.139.</citation>
    <PMID>20625050</PMID>
  </reference>
  <reference>
    <citation>Michels S. Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol. 2006 Nov;90(11):1333-4.</citation>
    <PMID>17057166</PMID>
  </reference>
  <reference>
    <citation>Ghazi NG, Kirk TQ, Knape RM, Tiedeman JS, Conway BP. Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration? Clin Ophthalmol. 2010 Apr 26;4:307-14.</citation>
    <PMID>20463798</PMID>
  </reference>
  <reference>
    <citation>El-Batarny AM. Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. Clin Ophthalmol. 2007 Jun;1(2):149-55.</citation>
    <PMID>19668504</PMID>
  </reference>
  <reference>
    <citation>Wong D, Joussen AM. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279. Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):161-2. doi: 10.1007/s00417-010-1603-7. Epub 2011 Jan 6.</citation>
    <PMID>21210141</PMID>
  </reference>
  <reference>
    <citation>Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol. 2007 Nov-Dec;55(6):417-20. Review.</citation>
    <PMID>17951896</PMID>
  </reference>
  <reference>
    <citation>Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007 Aug;16(5):437-9.</citation>
    <PMID>17700285</PMID>
  </reference>
  <reference>
    <citation>Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, Brito M, Alezzandrini AA, Restrepo N, Berrocal MH, Saravia M, Farah ME, Fromow-Guerra J, Morales-Canton V. Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol. 2011;2011:584238. doi: 10.1155/2011/584238. Epub 2011 Mar 30.</citation>
    <PMID>21584260</PMID>
  </reference>
  <reference>
    <citation>Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006 Mar;26(3):257-61.</citation>
    <PMID>16508423</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arrowhead Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Sonia Dhoot</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>pterygium</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>recurrence of pterygium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

